Influvac Tetra

Influenza virus vaccine, quadrivalent, the active ingredient in Influvac Tetra, is a preventive vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is used to protect individuals against influenza caused by virus types A and B.

GNH USA supplies Influvac Tetra as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Influvac Tetra is a quadrivalent influenza vaccine indicated for prevention of influenza infection across the seasonal virus family. - Seasonal influenza: induces immunity to prevent infection with circulating influenza A and B viruses. - Pandemic influenza preparedness: contributes to population immunity against potential pandemic strains. - High‑risk groups (elderly, children, chronic disease patients): lowers incidence and severity of influenza.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness or swelling: localized erythema or edema. - Low‑grade fever: transient temperature rise within 24‑48 hours. - Headache or muscle aches: mild systemic symptoms.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder that may follow vaccination. - Seizures: uncommon neurologic event, especially in children with fever.

Influvac Tetra should be administered with consideration of the following precautions. - Allergy assessment: avoid if the patient has a severe allergic reaction to any vaccine component. - Acute illness: postpone vaccination if the individual has a moderate or severe febrile illness. - Pregnancy: consult a healthcare professional before use. - Immunocompromised status: vaccine may be less effective; clinical judgment required. - Age limitation: not approved for children younger than six months. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac Tetra may have the following interaction considerations. Major Interactions (Avoid): - Live vaccines: concurrent administration can reduce efficacy of either vaccine. - Immunoglobulin therapy: may interfere with the immune response to the vaccine. - Antiviral agents (e.g., oseltamivir) given within 48 hours: may diminish antibody production. Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: may lower the vaccine‑induced antibody response. - Antipyretic medications: can mask post‑vaccination fever, making monitoring of reactions more difficult.